Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

La prise en charge thérapeutique de la sclérose en plaques est un domaine en plein essor depuis le début des années 1990. Elle a commencé par voir l'émergence des interférons et autres formes parentérales qui ont permis un ralentissement de la progression de la maladie et de la survenue des crises. Malheureusement , leur mode d'administration est un sérieux frein à la bonne compliance du patient. C'est pourquoi, depuis peu, l'arsenal thérapeutique de la maladie compte désormais des molécules à usage oral. Actuellement, elles sont au nombre de quatre. Le Gilenya® (fingolimod) est le premier à avoir fait son apparition en Belgique voici trois ans. Il a été suivi par l'Aubagio® (tériflunomide) qui fut approuvé par l'Agence Européenne du Médicament (EMA) fin 2013 et est en attente de commercialisation (prévue pour octobre 2014). Le Tecfidéra® (BG-12) est le troisième composé aggréé par l'EMA en janvier 2014 mais il n'est pas encore disponible dans notre pays. Sa mise à disposition a démarré mi-mai à la clinique universitaire de Saint Luc par un plan médical d'urgence comme c'est le cas pour l'Aubagio®. Enfin, le Nerventra® (laquinimod) a, pour sa part, reçu un avis négatif du CHMP le 23 janvier 2014 dans le traitement de la sclérose en plaques récurrente-rémittente en raison d'une suspicion d'effets cancérigènes à long terme. Cependant, une étude est toujours en cours pour la prise en charge de la forme progressive.Étant donné le caractère récent de ces nouvelles thérapies, l'innocuité à long terme doit encore est confirmée. Il n'empêche que ces traitements constituent une belle avancée dans la prise en charge de la sclérose en plaques améliorant considérablement la qualité de vie des patients. The therapeutic management of multiple sclerosis is a growing field since the early 1990s. It began to see the emergence of interferons and other parenteral forms the allowed a slower disease progression and a decrease of the occurrence of crises. Unfortunately, their administration is a serious hindrance to a good patient compliance. So, recently the armamentarium of the disease now has molecules for oral use. Currently, they are four in number. Gilenya (fingolimod) is the first to have appeared in Belgium, three years ago. It was followed by Aubagio (teriflunomide), which was approved by the EMA in late 2013 and is awaiting marketing (scheduled for October 2014). Tecfidera (BG-12) is the third compound approved by the EMA in January 2014 but is not yet available in our country. Its provision started in the middle of May at the university clinic of Saint Luke, with a medical emergency as it’s the case for Aubagio. Finally, Nerventra (laquinimod), for its part, received a negative opinion from CHMP January 23, 2014 in the therapeutic management of relapsing – remitting multiple sclerosis due to suspected carcinogenic effects on the long term.However, a study is ongoing to support the progressive form. Given the recent nature of these new therapies, long-term safety has yet to be confirmed. Nevertheless, such treatments are a great step forward in the treatment of multiple sclerosis considerably improving the quality of life of patients.

Multiple Sclerosis --- Multiple Sclerosis

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Multiple sclerosis is a chronic neurological disorder with devastating, long-term complications. MS is incurable, and most therapies treat only the symptoms leaving the patient with a reduced quality of life for extended periods of time. Most available therapeutic strategies target symptomatology, and not the pathophysiology of the disease. This book focuses on different biological pathways associated with MS and contains current information on the prevalence of multiple sclerosis, novel treatments that target pathophysiology, and new approaches for management of the disorder, as well as general knowledge about the disease process.

Multiple sclerosis. --- Multiple Sclerosis

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Multiple sclerosis. --- Multiple Sclerosis.

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Multiple sclerosis is a chronic neurological disorder with devastating, long-term complications. MS is incurable, and most therapies treat only the symptoms leaving the patient with a reduced quality of life for extended periods of time. Most available therapeutic strategies target symptomatology, and not the pathophysiology of the disease. This book focuses on different biological pathways associated with MS and contains current information on the prevalence of multiple sclerosis, novel treatments that target pathophysiology, and new approaches for management of the disorder, as well as general knowledge about the disease process.

Multiple sclerosis. --- Multiple Sclerosis

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Multiple sclerosis --- Multiple Sclerosis.